BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31598340)

  • 1. Weight Gain during Neoadjuvant Chemotherapy is Associated with Worse Outcome among the Patients with Operable Breast Cancer.
    Fang Q; Huang J; Gan L; Shen K; Chen X; Wu B
    J Breast Cancer; 2019 Sep; 22(3):399-411. PubMed ID: 31598340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of body mass index on pathological complete response and survival of breast cancer patients receiving neoadjuvant chemotherapy.
    Aguiar D; Ros L; Pérez D; Croissier L; Mori M; Hernández M; Vargas AM; Galván S; Antonilli C; Saura S
    Breast Dis; 2022; 41(1):351-361. PubMed ID: 36031886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Multicenter Study of the Impact of Body Mass Index (BMI) on the incidence of Pathologic Complete Response (pCR) Among Saudi Patients with locally advanced Breast cancer (LABC) post Neoadjuvant Chemotherapy (NAC).
    Al-Saleh K; Abd El-Aziz N; Ali A; Abo Zeed W; Salah T; Elsamany S; Rasmy A; El Farargy O; Husain S; Al-Rikabi A; Alsaeed E; Aldiab A; Abd El-Warith A
    Gulf J Oncolog; 2019 May; 1(30):33-42. PubMed ID: 31242980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes.
    Kogawa T; Fujii T; Fouad TM; Liu DD; Harano K; Masuda H; Iwase T; Barnett C; Park YS; Lim B; Tripathy D; Litton JK; Ueno NT
    Breast Cancer Res Treat; 2018 Sep; 171(2):501-511. PubMed ID: 29915946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer.
    Litton JK; Gonzalez-Angulo AM; Warneke CL; Buzdar AU; Kau SW; Bondy M; Mahabir S; Hortobagyi GN; Brewster AM
    J Clin Oncol; 2008 Sep; 26(25):4072-7. PubMed ID: 18757321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Body Mass Index- and Actual Weight-Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer.
    Raman R; Mott SL; Schroeder MC; Phadke S; El Masri J; Thomas A
    Clin Breast Cancer; 2016 Dec; 16(6):480-486. PubMed ID: 27431461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy.
    Takada K; Kashiwagi S; Asano Y; Goto W; Ishihara S; Morisaki T; Shibutani M; Tanaka H; Hirakawa K; Ohira M
    BMC Cancer; 2021 Oct; 21(1):1129. PubMed ID: 34670511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic and Prognostic Significance of Body Mass Index (BMI) among Breast Cancer Patients in Western China: A Retrospective Multicenter Cohort Based on Western China Clinical Cooperation Group (WCCCG).
    Wang K; Wu YT; Zhang X; Chen L; Zhu WM; Zhang AJ; Zheng K; Yin XD; Li F; Kong LQ; Ma BL; Li H; Liu JP; Jiang J; Li ZY; Shi Y; Ren GS; Li HY
    Biomed Res Int; 2019; 2019():3692093. PubMed ID: 31119166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term and long-term outcomes of oesophagogastric surgery for cancer in obese and normal weight patients.
    Glatz T; Kulemann B; Kuvendjiska J; Fichtner-Feigl S; Hoeppner J
    ANZ J Surg; 2020 Mar; 90(3):277-282. PubMed ID: 31854089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
    Yang X; Rao J; Yang W; Shui R
    Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation.
    Keilty D; Nezafat Namini S; Swain M; Maganti M; Cil TD; McCready DR; Cescon DW; Amir E; Fleming R; Mulligan AM; Fyles A; Croke JM; Liu FF; Levin W; Koch CA; Han K
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):676-685. PubMed ID: 32407932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05).
    Shim SJ; Park W; Huh SJ; Choi DH; Shin KH; Lee NK; Suh CO; Keum KC; Kim YB; Ahn SD; Kim SS; Ha SW; Chie EK; Kim K; Shin HS; Kim JH; Lee HS
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):65-72. PubMed ID: 24161425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Body Mass Index on Pathological Response after Neoadjuvant Chemotherapy: Results from the I-SPY 2 trial.
    Wang H; Yee D; Potter D; Jewett P; Yau C; Beckwith H; Watson A; O'Grady N; Wilson A; Brain S; Pohlmann P; Blaes A
    Res Sq; 2023 May; ():. PubMed ID: 37397981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial.
    Widschwendter P; Friedl TW; Schwentner L; DeGregorio N; Jaeger B; Schramm A; Bekes I; Deniz M; Lato K; Weissenbacher T; Kost B; Andergassen U; Jueckstock J; Neugebauer J; Trapp E; Fasching PA; Beckmann MW; Schneeweiss A; Schrader I; Rack B; Janni W; Scholz C
    Breast Cancer Res; 2015 Sep; 17(1):129. PubMed ID: 26385214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.
    Iwase M; Ando M; Aogi K; Aruga T; Inoue K; Shimomura A; Tokunaga E; Masuda N; Yamauchi H; Yamashita T; Iwata H
    Breast Cancer Res Treat; 2020 Apr; 180(3):687-694. PubMed ID: 32140811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U; Cabello C; Ramalho SOB; Zeferino LC
    BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WITHDRAWN: Effect of obesity at the pathologic response to neoadjuvant chemotherapy among premenopausal Tunisian women with breast cancer.
    Kacem M; Awatef M; Amel L; Jihen M; Slim BA
    Obesity (Silver Spring); 2010 May; ():. PubMed ID: 20448536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial.
    Martel S; Lambertini M; Agbor-Tarh D; Ponde NF; Gombos A; Paterson V; Hilbers F; Korde L; Manukyants A; Dueck A; Maurer C; Piccart M; Moreno-Aspitia A; Desmedt C; Di Cosimo S; de Azambuja E
    J Natl Compr Canc Netw; 2021 Jan; 19(2):181-189. PubMed ID: 33401235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.